Feeds:
Posts
Comments

AGENDA – ICI Meeting 2015 – International Conference for Innovations in Cardiovascular Systems (Heart, Brain and Peripheral Vessels) and High-Tech Life Science Industry, December 13-15, 2015, David InterContinental Hotel, Tel Aviv, Israel

AGENDA – ICI Meeting 2015 – International Conference for Innovations in Cardiovascular Systems (Heart, Brain and Peripheral Vessels) and High-Tech Life Science Industry, December 13-15, 2015, David InterContinental Hotel, Tel Aviv, Israel

Reporter: Aviva Lev-Ari, PhD, RN

Dear Colleagues,
It is with great pleasure that we invite you to the ICI Meeting 2015, to be held on December 13-15, at the David InterContinental Hotel, Tel Aviv, Israel – the premier International Conference for Innovations in cardiovascular systems (Heart Brain and Peripheral Vessels) and High-Tech Life Science Industry.ICI aims to explore, fuel spark and be part of the innovations that will shape the future of our cardiovascular systems and BEYOND.

Over the last 2 decades, Israel has turned into a medical start up nation and ICI has contributed to this process by facilitating the global interaction and building bridges of innovations between Israel, and the world, expanding as far west as California and as far east as China and Japan.

The route of the ICI meeting takes you through the process of innovation- starting from the ICI Academy of Innovation where we learn and exercise how to innovate, we then continue to a 2 days conference focusing on the use of advanced technologies to save hearts and lives. We challenge the horizons in coronary and vascular interventions, transcatheter valvular therapies, stroke prevention and intervention and heart failure. We explore the treatment of hypertension with renal denervation, have a special track on digital health, mobile solutions and the Cellular Revolution, and have some fascinating lectures by the leading professional in our field.

We invite you, Physicians, Nurses, Technicians, Researchers, Entrepreneurs, Investor, Engineers, Venture Capital Firms, Private Equity Firms, Patent Experts, Pharmaceutical Companies, and Medical Device Companies to join us at ICI 2015, and we are certain that each one of you will find his/her field of interest and be updated on other related fields.
By the end of the meeting you will walk out with a better understanding of the frontiers in each field, with unmet needs in our disciplines and with many new ideas.

Enjoy ICI; enjoy Tel Aviv; enjoy Israel.

ICI Mission:

  • Innovation- Focus on the Process and Not on the Outcomes

To bring the most advanced cutting-edge innovative technologies and therapies in the cardiovascular systems
(Heart Brain and Peripheral Vessels) and to help guide innovators through the process of innovation.

  • Academy- The “how” of Innovation

To focus on education regarding the entire medical innovation process, bringing together parties involved
in all phases of the innovation process to provide knowledge, insights and views.

  • Science- Share News & Announcements

To enable public and private discussions around issues relevant to the innovation process.
Transition the ICI meeting to a continuous, 365-days a year experience

  • Industry- Learn from Experiences

Network with the leading, most experienced companies in the industry

 

Sincerely yours,
Beyar-WEB Lotan-WEB
Rafael Beyar Chaim Lotan
 Meeting Directors
On behalf of the Organizing Committee

 

 

WHAT IS ICI

It is with great pleasure that we invite you to the ICI Meeting 2015 – the premier International Conference for Innovations in cardiovascular systems (Heart Brain and Peripheral Vessels) and High-Tech Life Science Industry.

ICI aims to explore, fuel spark and be part of the innovations that will shape the future of our cardiovascular systems and BEYOND.

Over the last 2 decades, Israel has turned into a medical start up nation and ICI has contributed to this process by facilitating the global interaction and building bridges of innovations between Israel, and the world, expanding as far west as California and as far east as China and Japan.

Conference Secretariat:
Paragon Israel (Dan Knassim)
Telefax: +972-3-5767730/7
Email: secretariat@icimeeting.com

 

VIEW VIDEO

https://www.youtube.com/watch?v=0BtZQG0n0To

 

PROGRAM – DAY 1

 

http://2015.icimeeting.com/wp-content/uploads/2015/07/ICI-2015-Preliminary-Program-Day-1-160815.pdf

 

PROGRAM – DAY 2

http://2015.icimeeting.com/wp-content/uploads/2015/07/ICI-2015-Preliminary-Program-Day-2-160815.pdf

 

REGISTRATION

http://2015.icimeeting.com/registration/

 

Other related articles 

AGENDA – ICI Conference – Innovation in Cardiovascular Interventions – December 14-16, at the David InterContinental Hotel, Tel Aviv, Israel

http://pharmaceuticalintelligence.com/2014/11/05/agenda-ici-conference-innovation-in-cardiovascular-interventions-december-14-16-at-the-david-intercontinental-hotel-tel-aviv-israel/

One Response

  1. This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

    A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.



Comments RSS

Leave a Reply

%d bloggers like this: